Larimar Therapeutics, Inc.
4.3100-0.04 (-0.92%)
Oct 29, 4:00:02 PM EDT · NasdaqGM · LRMR · USD
Key Stats
Market Cap
368.89MP/E (TTM)
-Basic EPS (TTM)
-1.57Dividend Yield
0%Recent Filings
8-K
Nomlabofusp data boosts FA hopes
Larimar Therapeutics updated its corporate presentation on October 14, 2025, highlighting positive open-label study data for nomlabofusp in Friedreich's ataxia. All participants achieved skin frataxin levels over 50% of healthy volunteers by six months, with median mFARS improvements of 2.25 after one year versus worsening in natural history controls. Nomlabofusp proved well-tolerated long-term, despite early anaphylaxis cases prompting a modified dosing regimen endorsed by the FDA. Cash stands at $175.7 million, funding into Q4 2026; BLA submission targets Q2 2026 for accelerated approval. Anaphylaxis risks persist early in treatment.
8-K
Positive nomlabofusp data boosts FA hopes
Larimar Therapeutics unveiled positive data from its ongoing open-label study of nomlabofusp in Friedreich's ataxia patients, showing sustained skin frataxin increases to over 50% of healthy volunteer levels in all 10 participants at six months, alongside directional improvements in four key clinical outcomes like mFARS after one year—contrasting with disease worsening in a natural history reference. While seven anaphylaxis cases prompted a modified starting dose regimen, which the FDA endorsed, long-term daily dosing proved generally well-tolerated. BLA submission for accelerated approval targets Q2 2026. Safety risks persist early in treatment.
10-Q
Q2 FY2025 results
Larimar Therapeutics posted a Q2 net loss of $26.2M, up 21% y/y from $21.6M, driven by R&D expenses climbing to $23.4M from $19.7M amid ramped-up nomlabofusp trials and manufacturing. Operating loss widened to $27.8M y/y, with diluted EPS slipping to $(0.41) on 64.0M shares, consistent with no anti-dilution effects. YTD net loss hit $55.5M, 53% higher y/y, as cash burn accelerated to $45.9M from operating activities, leaving $138.5M in cash and equivalents at quarter-end; a $65.1M stock offering in July bolsters runway into Q4 2026. Progress shines in the open label study, now dosing at 50mg with FDA nods for skin FXN as a surrogate endpoint toward a Q2 2026 BLA. Cash flows freely from maturities. Yet regulatory delays could stall the path.
8-K
Larimar Q2 loss widens
Larimar Therapeutics reported Q2 2025 net loss of $26.2 million, up from $21.6 million last year, driven by higher R&D spending on nomlabofusp trials for Friedreich's ataxia. The company raised $65.1 million in a July offering, boosting pro forma cash to $203.6 million for a runway into Q4 2026. BLA submission for accelerated approval stays on track for Q2 2026, with key data from open-label and adolescent studies due in September. FDA risks loom large.
8-K
Larimar raises $64.4M via stock offering
Larimar Therapeutics priced a public offering of 18.75 million shares at $3.20 each on July 29, 2025, with underwriters exercising their full option for 2.81 million more shares. The deal closes July 31, yielding net proceeds of $64.4 million after fees. This cash infusion bolsters the biotech's runway amid development pushes. Yet risks lurk in market volatility.
BLRX
BioLineRx Ltd.
3.50-0.18
BMRN
BioMarin Pharmaceutical Inc.
51.86-1.63
IMMX
Immix Biopharma, Inc.
3.72-0.18
KALA
KALA BIO, Inc.
0.80-0.03
LBRX
LB Pharmaceuticals Inc
15.65-0.92
LIMN
Liminatus Pharma, Inc.
1.42+0.00
LSTA
Lisata Therapeutics, Inc.
2.66-0.12
MRKR
Marker Therapeutics, Inc.
0.97-0.04
OMER
Omeros Corporation
7.68-0.28
RLMD
Relmada Therapeutics, Inc.
2.45+0.00